Developer of the novel AVIDIO Platform
RNA-based artificial
virus platform
Capacity to deliver
multiple transgenes
Broad spectrum of
immune responses
Focus on
immuno-oncology
CaroGen Highlights
Developed novel AVIDIO platform
that delivers multiple transgenes
Artificial Virus for Infectious
Diseases &
Immuno-Oncology
Two candidates in late stage pre-clinical (IND enabling) studies
CARG-2020 for ovarian cancer; CARG-201 for Chronic Hepatitis B
Broad and expanding patent portfolio
Issued composition of matter and methods of use patents
HBV program supported by over $10 million in NIH & DoD grants
Expect continued support for Phase 1 clinical studies
Our Team
Founders
Bijan Almassian, phD
Chief Executive Officer
Valerian Nakaar, PhD
Chief Scientific Officer
John Rose, PhD
Chairman
Scientific Advisory Board
Michael Robek, PhD
Member
Scientific Advisory Board
Our Press Releases
CaroGen News.
Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer Models
Ayesha Alvero, MD, MSc, professor, Department of Obstetrics and Gynecology, Wayne State...
Novel Immunomodulatory virus CARG-2020 for Recurrent ovarian cancer
At the 2023 Society of Gynecological Oncology’s Annual Meeting on Women’s Cancer in Tampa,...
CaroGen’s CARG-2020 Preclinical Data on Ovarian Cancer Immunotherapy...
Farmington, CT, November 8, 2022 – CaroGen Corporation (https://carogencorp.com)...
CaroGen Management to Speak at The World Vaccine & Immunotherapy Congress
Farmington, CT, September 5, 2022– CaroGen Corporation (https://carogencorp.com)...
Bijan Almassian, PhD. on LinkedIn: CaroGen in pact with NIH to develop flu vaccine...
We are honored to be working with NIAID/NIH scientists to develop a universal influenza vaccine...
“Relational Contract” Supports Outsourcing Of Hepatitis B Immunotherapy
Striving to develop CARG-201 as a novel immunotherapy for potential functional cure of over 250 million patients worldwide...
CaroGen and Wayne State University scientists report significant progress...
Farmington, Conn., Oct. 25, 2020 – Privately-held CaroGen Corp., in collaboration with a team of scientists...
UConn Health, CaroGen Collaborate on Promising Technology...
UConn Health researchers, along with industry partners, have developed a promising potential candidate...
Our Press Releases
CaroGen News.
Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer Models
Ayesha Alvero, MD, MSc, professor, Department of Obstetrics and Gynecology, Wayne State...
Novel Immunomodulatory virus CARG-2020 for Recurrent ovarian cancer
At the 2023 Society of Gynecological Oncology’s Annual Meeting on Women’s Cancer in Tampa,...
CaroGen’s CARG-2020 Preclinical Data on Ovarian Cancer Immunotherapy...
Farmington, CT, November 8, 2022 – CaroGen Corporation (https://carogencorp.com)...
CaroGen Management to Speak at The World Vaccine & Immunotherapy Congress
Farmington, CT, September 5, 2022– CaroGen Corporation (https://carogencorp.com)...
Bijan Almassian, PhD. on LinkedIn: CaroGen in pact with NIH to develop flu vaccine...
We are honored to be working with NIAID/NIH scientists to develop a universal influenza vaccine...
“Relational Contract” Supports Outsourcing Of Hepatitis B Immunotherapy
Striving to develop CARG-201 as a novel immunotherapy for potential functional cure of over 250 million patients worldwide...
CaroGen and Wayne State University scientists report significant progress...
Farmington, Conn., Oct. 25, 2020 – Privately-held CaroGen Corp., in collaboration with a team of scientists...
UConn Health, CaroGen Collaborate on Promising Technology...
UConn Health researchers, along with industry partners, have developed a promising potential candidate...